Clinical outcomes of intravitreal treatment for ocular toxoplasmosis: systematic review and meta-analysis
ABSTRACT Background: Ocular toxoplasmosis is the leading cause of infectious posterior uveitis worldwide, accounting for 30-50% of all cases in immunocompetent patients. Conventional treatment is associated with adverse effects and does not prevent recurrence. Intravitreal drug administration can...
Main Authors: | Lutiana Amaral de Melo, Mayara Rodrigues Brandão de Paiva, Gabriella Maria Fernandes-Cunha, Armando Silva-Cunha, Marcos Paulo Gomes Mol, Sílvia Ligorio Fialho |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Brasileira de Medicina Tropical (SBMT)
2023-05-01
|
Series: | Revista da Sociedade Brasileira de Medicina Tropical |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822023000100319&lng=en&tlng=en |
Similar Items
-
Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis
by: Rodrigo Jorge, MD, PhD, et al.
Published: (2021-06-01) -
OCULAR TOXOPLASMOSIS
by: Iskren Kaftandjiev, et al.
Published: (2021-04-01) -
Toxoplasmosis and its Ocular Manifestations
by: Koev Kr.
Published: (2014-06-01) -
In vitro and in vivo anti−Toxoplasma activities of HDAC inhibitor Panobinostat on experimental acute ocular toxoplasmosis
by: Yu Zhang, et al.
Published: (2022-09-01) -
La Toxoplasmosis ocular.
by: Daniel Leiva Rojas, et al.
Published: (2022-08-01)